BRIEF published on 05/21/2026 at 19:29, 3 months 25 days ago EMA Accepts Teva's Application for Long-Acting Schizophrenia Treatment Schizophrenia Treatment Teva Pharmaceuticals EMA Approval Olanzapine Injectable Long-acting Formulation
PRESS RELEASE published on 05/21/2026 at 19:24, 3 months 25 days ago Inside Information / Other news releases European Medicines Agency accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable to treat schizophrenia in adults. Teva and Medincell announce EMA acceptance for innovative treatment option Schizophrenia Medincell Olanzapine Teva EMA
BRIEF published on 04/29/2026 at 13:44, 4 months 17 days ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
BRIEF published on 04/29/2026 at 13:44, 4 months 17 days ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
PRESS RELEASE published on 04/29/2026 at 13:39, 4 months 17 days ago Inside Information / Other news releases Medincell's partner Teva Pharmaceuticals reports UZEDY Q1 2026 net sales of $63M, a 62% increase year-on-year. Olanzapine LAI NDA accepted by FDA. Medincell focuses on long-acting injectable treatments across various therapeutic areas Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Long-acting Injectable
BRIEF published on 04/20/2026 at 11:18, 4 months 26 days ago BNP Paribas Développement crosses a threshold at MEDICELL Euronext Paris Voting Rights BNP Paribas Threshold Crossing MEDICELL
BRIEF published on 04/02/2026 at 19:05, 5 months 13 days ago Medincell: Update on capital and voting rights Share Capital Voting Rights Shares Euronext AMF
BRIEF published on 02/20/2026 at 21:42, 6 months 23 days ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
PRESS RELEASE published on 02/20/2026 at 21:37, 6 months 23 days ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
BRIEF published on 02/19/2026 at 10:33, 6 months 25 days ago Mirova crosses a threshold at MEDINCELL Euronext Paris Voting Rights Transfer Of Shares Mirova MEDICELL
Published on 09/16/2026 at 15:00, 43 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 1 hour 43 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/16/2026 at 13:30, 2 hours 13 minutes ago Sterling Extends Core MEPS Copper Zone to 700m; Intersects 200m of 0.53% CuEq Including 102m of 0.81% CuEq
Published on 09/16/2026 at 13:23, 2 hours 20 minutes ago SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 13:15, 2 hours 28 minutes ago Impauer Technologies Announces Launch Of New Corporate Website And Provides OTC Symbol Update
Published on 09/16/2026 at 07:00, 8 hours 43 minutes ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 21 hours 43 minutes ago Report on the Combined General Meeting of the 10th of September 2026
Published on 09/15/2026 at 17:45, 21 hours 58 minutes ago EURAZEO COMPLETES THE ACQUISITION OF NETCO GROUP
Published on 09/15/2026 at 17:01, 22 hours 41 minutes ago Number of shares and voting rights - August 2026 (In French only)
